This section provides explanatory text for each question on the Pre-CTED, Pre-CTED Baseline, Cellular Therapy Product, Cellular Therapy Infusion, Post-CTED, and Post-CTED Follow-up forms.
4000: Cellular Therapy Essential Data Pre-Infusion
4001: Pre-Cellular Therapy Baseline Data
4003: Cellular Therapy Product
4006: Cellular Therapy Infusion
4100: Cellular Therapy Essential Data Follow-Up
4101: Post-Cellular Therapy Follow-Up
More information about cell therapy reporting is available in the Data Management Guide, Cell Therapy
Cell Therapy Training Resources
CIBMTR Guidance Document for Reporting Autologous Cell Therapies
Cell Therapy Reporting Preferences
Cell Therapy Reporting Levels
Cell Therapy Reporting Tracks and Follow-Up Schedules
How Forms Come Due
Combined Follow-Up Scenarios (HCT + CT (Genetically Modified))
Common Cell Therapy Related Questions
Donor cellular infusion (DCI)
Donor cellular infusions (DCIs) are a subtype of cellular therapy. An infusion can be classified as a “DCI” when:
- The intent is something other than to restore hematopoiesis
- The infusion must be post-HCT, often by the same donor as the HCT
- Indication is suboptimal donor chimerism, immune reconstitution, GVHD treatment, prevent or treat disease relapse (as reported on F4000)
*Composition of cells include mesenchymal cells, peripheral blood mononuclear cells, NK cells, etc.
Donor Lymphocyte Infusions (DLIs) are a subset of DCIs. DLIs meet the same criteria above but are infusions of just a lymphocyte product. DLIs are reported on the Donor Lymphocyte Infusion (2199) form. See the F2199 manual for the definition of DLI.
Need more help with this?
Don’t hesitate to contact us here.